TaiGen Biopharmaceuticals Holdings Limited

Taipei Exchange 4157.TWO

TaiGen Biopharmaceuticals Holdings Limited Shares (Diluted, Weighted) for the year ending December 31, 2023: 717,271,000

TaiGen Biopharmaceuticals Holdings Limited Shares (Diluted, Weighted) is 717,271,000 for the year ending December 31, 2023, a 0.06% change year over year. Shares (diluted, weighted) are the number of outstanding shares used to calculate earnings per share (EPS) assuming the conversion of all potentially dilutive securities.

TaiGen Biopharmaceuticals Holdings Limited Shares (Diluted, Weighted) for the year ending December 31, 2022 was 716,844,000, a -0.07% change year over year.
TaiGen Biopharmaceuticals Holdings Limited Shares (Diluted, Weighted) for the year ending December 31, 2021 was 717,363,000, a 0.07% change year over year.
TaiGen Biopharmaceuticals Holdings Limited Shares (Diluted, Weighted) for the year ending December 31, 2020 was 716,841,000, a 0.01% change year over year.
TaiGen Biopharmaceuticals Holdings Limited Shares (Diluted, Weighted) for the year ending December 31, 2019 was 716,805,000, a 0.01% change year over year.

Key data

Date	Shares (Diluted, Weighted)	Revenue	Cost of Revenue	Gross Profit

Taipei Exchange: 4157.TWO

TaiGen Biopharmaceuticals Holdings Limited

CEO	Mr. Kuo-Lung Huang
IPO Date	Aug. 30, 2013
Location	Taiwan
Headquarters	No. 138, Xinming Road
Employees	52
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

TaiGen Biopharmaceuticals Holdings Limited, a pharmaceutical company, develops novel therapeutics for transformative diseases worldwide. The company develops Taigexyn (Nemonoxacin), a non-fluorinated quinolone antibiotic for the treatment of bacterial infections. It is also developing Taigexyn for treating community-acquired pneumonia and diabetic foot infection, as well as other bacterial infections; Burixafor, a stem cell mobilizer for stem cell transplantation and chemosenzitization; TG-1000, an influenza antiviral drug for treating influenza A, B, and avian influenza H7N9; and Furaprevir, a hepatitis C virus protease inhibitor for the treatment of chronic hepatitis C. The company was founded in 2001 and is based in Taipei City, Taiwan.

Key trends

Past 5 years